Illustrative image (Source: AFP/VNA)The two vaccine products are entering the finalphase of clinical trials, she said.
Indovac, with a sub-unit recombinant proteinplatform, was developed by the Eijkman Institute for Molecular Biology alongwith the state-owned pharmaceutical company, PT Bio Farma, and Baylor Collegeof Medicine.
Meanwhile, the Inavec vaccine, with an inactivatedvirus platform, is developed by the Research Team from Airlangga University(Unair) in collaboration with production facility provider PT BiotisPharmaceutical Indonesia, she revealed.
Lukito targets the Indovac and Inavec vaccines toobtain an emergency use authorisation (EUA) from BPOM in September 2022.
Both vaccines have passed phase two of the clinicaltrial with good results. They are able to improve the immune system, and theresults are not inferior to vaccines that have received EUA with the sametechnology, she remarked.
Currently, the BPOM is still conducting a review ofresearch reports on thousands of subjects that received a second injection ineach trial laboratory.
The third phase of clinical trials of the twodomestic vaccines is also accompanied by the granting of permits for clinicaltrial activities for booster vaccines or booster doses, she said./.
VNA
